UBS Reiterates Buy Rating on CG Oncology (CGON) as AUA 2026 Abstracts Released

April 28, 2026 9:07 AM

UBS analyst David Dai reiterated a Buy rating and $90.00 price target on CG Oncology (NASDAQ: CGON).The analyst commented, "AUA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found